BOSTON, November 3, 2021 – GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing
Beyond Meat (BYND) was one of last year’s hottest stocks. Shares of the plant-based meat company exploded 859% during its first three months out of the gate.
“DNA is like a computer program but far, far more advanced than any software ever created.”
Bill Gates wrote this in 1995, long before synthetic biology – a scientific discipline focused on reading, writing, and editing DNA – was being harnessed to program living cells.
By altering the genetic code in bacteria, researchers have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs’ effectiveness and convenience.
A year ago, a group of scientists convened in New York City to discuss an audacious plan: construct an entire human genome from scratch.